IDEX BIOMETRICS ASA financials
IDEX BIOMETRICS ASA
5967007LIEEXZXHECW11 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | $841.0K | $4.1M |
| Operating expenses | $22.7M | $31.0M |
| Employee benefits expense | $8.8M | $14.3M |
| Depreciation & amortisation | $2.5M | $1.6M |
| Operating profit (EBIT) | -$21.9M | -$26.8M |
| Finance costs | $2.4M | $639.0K |
| Profit before tax | -$14.6M | -$26.6M |
| Income tax expense | -$120.0K | -$16.0K |
| Profit for the year | -$14.4M | -$26.6M |
| Total comprehensive income | -$14.3M | -$27.1M |
| Per share | ||
| Basic EPS | $-0.03 | $-0.11 |
| Diluted EPS | $-0.03 | $-0.11 |
| Cash flow statement | ||
| Net cash from operating activities | -$17.5M | -$27.0M |
| Net cash from investing activities | $272.0K | $4.0K |
| Net cash from financing activities | $7.9M | $22.2M |
| Proceeds from borrowings | $0 | $8.6M |
| Repayments of borrowings | $2.7M | $0 |
| Lease liability payments | $596.0K | $671.0K |
| Net change in cash | -$9.3M | -$4.8M |
| Balance sheet | ||
| Total assets | $10.3M | $25.0M |
| Non-current assets | $1.0M | $4.7M |
| Property, plant & equipment | $122.0K | $812.0K |
| Right-of-use assets | $293.0K | $1.8M |
| Intangible assets & goodwill | $0 | $968.0K |
| Current assets | $9.3M | $20.3M |
| Inventories | $5.5M | $6.4M |
| Trade & other receivables | $30.0K | $949.0K |
| Cash & equivalents | $2.0M | $11.4M |
| Total equity | $4.7M | $11.3M |
| Non-current liabilities | $2.1M | $1.2M |
| Long-term borrowings | $2.0M | $0 |
| Lease liabilities (non-current) | $0 | $1.2M |
| Current liabilities | $3.5M | $12.4M |
| Short-term borrowings | $0 | $5.1M |
| Lease liabilities (current) | $396.0K | $624.0K |
| Derived metrics | ||
| Operating margin | -2604.4% | -648.8% |
| Net margin | -1718.1% | -643.5% |
| Return on equity | -306.6% | -234.9% |
| Cash conversion ratio | 1.21× | 1.01× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | $836.0K | -$1.9M |
| Adjustments For Decrease Increase In Trade Account Receivable | $1.0M | $370.0K |
| Adjustments For Depreciation and Amortisation Expense | $2.5M | $1.6M |
| Adjustments For Increase Decrease In Trade Account Payable | $165.0K | -$852.0K |
| Adjustments For Sharebased Payments | $351.0K | $1.3M |
| Capital Redemption Reserve | $321.3M | $300.5M |
| Current Prepaid Expenses | $764.0K | $648.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -$2.0K | $3.0K |
| Equity and Liabilities | $10.3M | $25.0M |
| Income Taxes Paid Refund Classified As Operating Activities | $129.0K | -$46.0K |
| Increase Decrease Through Conversion of Convertible Instruments | $521.0K | — |
| Increase Decrease Through Sharebased Payment Transactions | $356.0K | $1.4M |
| Increase Decrease Through Transfers and Other Changes Equity | — | $0 |
| Intangible Assets Other Than Goodwill | $569.0K | $1.0M |
| Interest Paid Classified As Operating Activities | $254.0K | $5.0K |
| Interest Received Classified As Investing Activities | $136.0K | $254.0K |
| Issue of Equity | $6.8M | $14.1M |
| Issued Capital | $12.9M | $26.0M |
| Liabilities | $5.6M | $13.6M |
| Miscellaneous Other Operating Expense | $7.3M | $8.7M |
| Noncurrent Receivables | $57.0K | $81.0K |
| Number of Shares Issued | 831.6M | 1397.0M |
| Number of Shares Outstanding | 831.6M | 1397.0M |
| Other Comprehensive Income | $108.0K | -$436.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | $108.0K | -$436.0K |
| Other Current Financial Liabilities | $652.0K | $3.5M |
| Other Current Liabilities | $1.3M | $2.2M |
| Other Current Receivables | $901.0K | $979.0K |
| Other Noncurrent Financial Liabilities | $139.0K | $0 |
| Par Value Per Share | $0.15 | $0.15 |
| Proceeds From Issuing Shares | $11.2M | $14.3M |
| Reduction of Issued Capital | $0 | — |
| Research and Development Expense | $2.5M | $2.4M |
| Reserve of Exchange Differences On Translation | -$12.0M | -$12.1M |
| Reserve of Sharebased Payments | $25.2M | $24.9M |
| Retained Earnings | -$344.5M | -$330.0M |
| Revenue From Rendering of Services | $141.0K | $8.0K |
| Revenue From Sale of Goods | $700.0K | $4.1M |
| Share Premium | $1.7M | $2.1M |
| Trade and Other Current Payables To Trade Suppliers | $850.0K | $688.0K |
Every line item above is a fact tagged in IDEX BIOMETRICS ASA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.